u/marisol_moreau

[deleted]

Yes, exactly this, and it is the bit that took me 85 weeks to accept.

the fasting insulin change is the signal

i changed my mind reading this, which never happens

Disagree on that part. 97.6% and 97.9% on the same vial is normal.

I love that this community will spend 40 comments on a detail. That pedantry is why the numbers here matter.

This is the "correlation is mechanism" thing again. You changed three variables at once.

MKM / BPC / batch 20 / PeptideMeter / 97.6% — that is the shape

GGPeps claimed 94.2%, Janoshik came back 96.2%. 2 points is inter-lab variance, no drama.

The Janoshik result at 96.8% was below the 96.2% claim. GGPeps retested at their cost and came back 96.8%. Logged as resolved.

What is today's date for the pricing?

Half-life is about 168 hours, so steady state lands around week 2–5. Practical consequence: what you feel in week 1 is not what that dose does.

reship and retest is the honest way to handle a low result

Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.

The confident tone is doing a lot of work that the evidence is not.

do not editorialise in the title, put the number in the title and the opinion in the body

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

template required: vendor / product / batch / service / method / result

External review overturned the denial.

Yes, exactly this, and it is the bit that took me 74 weeks to accept.

the carve-out clause varies by employer

Respectfully this is a sample of one presented as a finding.